IP3R-III アクチベーター

The IP3R-II activators comprise a diverse set of compounds that directly or indirectly influence the activity of IP3R-II, a critical player in intracellular calcium signaling. Notably, substances like 2-APB and Xestospongin C act as IP3 receptor antagonists, with 2-APB inhibiting IP3 binding and Xestospongin C specifically targeting IP3R-II. These compounds modulate the release of calcium from intracellular stores, impacting cellular processes regulated by intracellular calcium signaling. On the other hand, compounds such as 8-Bromo-cADPR and Ruthenium Red showcase indirect modulation of IP3R-II. 8-Bromo-cADPR enhances the sensitivity of IP3R-II to IP3, leading to increased calcium release. In contrast, Ruthenium Red, a non-specific IP3 receptor inhibitor, blocks calcium release from intracellular stores. These compounds collectively highlight the intricate regulatory mechanisms involved in IP3R-II activation and its role in calcium signaling. Additionally, modulators like U73122 and Carbachol influence IP3R-II indirectly through pathways involving phospholipase C (PLC) activation. U73122 inhibits PLC, reducing IP3 levels and subsequently affecting IP3R-II activation. Carbachol, through muscarinic acetylcholine receptor activation, triggers PLC-mediated IP3 production, leading to altered calcium release from intracellular stores.

Other compounds like ATP and Miconazole showcase the influence of purinergic receptors and inositol monophosphatase inhibition, respectively, on IP3R-II activity. ATP, through purinergic receptors, activates PLC and increases IP3 production, ultimately affecting IP3R-II activation. Miconazole, by blocking inositol monophosphatase, reduces IP3 availability, impacting IP3R-II activation and calcium release. BAPTA-AM and Procaine, as calcium chelator and PLC inhibitor, respectively, directly or indirectly modulate IP3R-II activity. BAPTA-AM sequesters intracellular calcium, altering IP3R-II activation and downstream signaling. Procaine, through PLC inhibition, decreases IP3 levels, influencing IP3R-II activity and calcium release.